• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Biogen Idec

NASDAQ:BIIB

$131.56 -$0.09 (-0.07%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

Biogen Tysabri Canadian Label Update - Analyst Blog

5/25/2012 by Nasdaq

Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades

5/24/2012 by Seeking Alpha

Wondering Which Stocks to Sell? There’s a List and We Explain How to Read It

5/24/2012 by YCharts

AVEO's AV-203 in Phase I - Analyst Blog

5/24/2012 by Nasdaq

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutic

5/21/2012 by Nasdaq

Data on Elan & Biogen's Tysabri - Analyst Blog

5/18/2012 by Nasdaq

How High Can Biogen Idec Fly?

5/16/2012 by DailyFinance

Your Warning Label Is My Sales Brochure

5/16/2012 by DailyFinance

Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novart

5/14/2012 by Nasdaq

UPDATE: FDA Concludes Safety Review Of Novartis MS Drug Gilenya

5/14/2012 by Smart Money

Drug Approval! Oh, Wait, We Knew That Already.

5/12/2012 by DailyFinance

Standard Review for Biogen's BG-12 - Analyst Blog

5/11/2012 by Nasdaq

Isis Loss Widens on Higher Expenses - Analyst Blog

5/9/2012 by Nasdaq

Top Analyst Upgrades & Downgrades (ACM, ALNY, BIIB, BP, COF, SNP, CTSH, EA, EPB, ERJ, F, LPX, MFC, M

5/8/2012 by 247wallst

Earnings Beat at PDL BioPharma - Analyst Blog

5/8/2012 by Nasdaq

Revenues Climb at Acorda - Analyst Blog

5/4/2012 by Nasdaq

Tysabri's Looking Good at a Crossroads

5/4/2012 by DailyFinance

Elan Misses 1Q EPS, Revenues Rise - Analyst Blog

5/1/2012 by Nasdaq

Stocks to watch Tuesday: Sears, Delta, Pfizer

5/1/2012 by MarketWatch

UPDATE: Biogen 1Q Profit Up, But Hurt By Purchasing Issue

5/1/2012 by Smart Money

Earnings Miss for Biogen - Analyst Blog

5/1/2012 by Nasdaq

2nd UPDATE: Biogen 1Q Profit Up, But Hurt By Purchasing Issue

5/1/2012 by Smart Money

When Will Spectrum's Run End?

4/30/2012 by DailyFinance

6 Buy-Rated Stocks With Encouraging Receivable Trends

4/27/2012 by DailyFinance

MDCO Beats, Ties with AstraZeneca - Analyst Blog

4/26/2012 by Nasdaq

Disappointing Results at Novartis - Analyst Blog

4/25/2012 by Nasdaq

Biogen Says Data Highlight Safety Profile For BG-12 MS Drug

4/24/2012 by Smart Money

Amgen Kicks Off Week of Big Biotech Earnings

4/24/2012 by Minyanville

Abbott Beats, Raises Outlook - Analyst Blog

4/18/2012 by Nasdaq

WSJ BLOG/Health: A Different Route to Finding a Treatment for Lou Gehrig's Disease

4/16/2012 by Smart Money

Whoa! These Stocks Head-Faked the Market

4/16/2012 by DailyFinance

Does Amgen Pass Buffett's Test?

4/15/2012 by DailyFinance

Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease

4/13/2012 by Smart Money

UPDATE: Novartis MS Pill Gilenya Patient Gets Rare Brain Disease

4/13/2012 by Smart Money

Biogen's Fampyra Launched in Canada - Analyst Blog

4/13/2012 by Nasdaq

After Hours Most Active for Apr 11, 2012 : NOK, QQQ, KFT, CX, BAC, STD, HCA, EVEP, BIIB, MU, FAST,

4/11/2012 by Nasdaq

Top Analyst Upgrades & Downgrades (AIG, BV, BIIB, BX, CIEN, IBM, MCD, NVO, SNDK, SON, LUV, SBUX, SYY

4/4/2012 by 247wallst

Surprise! Carl Icahn Has Opinion About This Biotech Sale Rumor

4/4/2012 by DailyFinance

Big Pharma Cozies Up to Biotech

3/30/2012 by DailyFinance

Biogen CEO's Total Compensation Up 20% To $11.3M Last Year

3/26/2012 by Smart Money
See More Articles...